173 related articles for article (PubMed ID: 30275685)
41. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
[TBL] [Abstract][Full Text] [Related]
42. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
43. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
44. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
[TBL] [Abstract][Full Text] [Related]
45. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Kelly CM; Green MC; Broglio K; Thomas ES; Brewster AM; Valero V; Ibrahim NK; Gonzalez-Angulo AM; Booser DJ; Walters RS; Hunt KK; Hortobagyi GN; Buzdar AU
J Clin Oncol; 2012 Mar; 30(9):930-5. PubMed ID: 22331946
[TBL] [Abstract][Full Text] [Related]
46. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Chen X; Ye G; Zhang C; Li X; Chen Y; Xie X; Zheng H; Cao Y; Wu K; Ni D; Tang J; Wei Z; Shen K
Breast Cancer Res Treat; 2013 Dec; 142(3):549-58. PubMed ID: 24292815
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA; Martin M; Jung KH; Huang CS; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Fasching PA; Afenjar K; Spera G; Lopez-Valverde V; Song C; Trask P; Boulet T; Sparano JA; Symmans WF; Thompson AM; Slamon D
J Clin Oncol; 2019 Sep; 37(25):2206-2216. PubMed ID: 31157583
[TBL] [Abstract][Full Text] [Related]
48. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
49. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Ohno S; Chow LW; Sato N; Masuda N; Sasano H; Takahashi F; Bando H; Iwata H; Morimoto T; Kamigaki S; Nakayama T; Nakamura S; Kuroi K; Aogi K; Kashiwaba M; Yamashita H; Hisamatsu K; Ito Y; Yamamoto Y; Ueno T; Fakhrejahani E; Yoshida N; Toi M
Breast Cancer Res Treat; 2013 Nov; 142(1):69-80. PubMed ID: 24122389
[TBL] [Abstract][Full Text] [Related]
50. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer.
Chen W; He J; Song S; Wang M; Wu H; Wang X
Oncol Lett; 2015 Apr; 9(4):1922-1926. PubMed ID: 25789069
[TBL] [Abstract][Full Text] [Related]
52. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
54. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
55. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
56. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
French Adjuvant Study Group
J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
[TBL] [Abstract][Full Text] [Related]
57. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig GW; Royce ME; Hunt KK
JAMA Oncol; 2019 Jan; 5(1):45-50. PubMed ID: 30193295
[TBL] [Abstract][Full Text] [Related]
58. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
[TBL] [Abstract][Full Text] [Related]
60. [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Liu K; Wang GB; Cheng B; Qiu DB
Ai Zheng; 2007 Apr; 26(4):427-30. PubMed ID: 17430667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]